DE69900249T2 - Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie - Google Patents

Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie

Info

Publication number
DE69900249T2
DE69900249T2 DE69900249T DE69900249T DE69900249T2 DE 69900249 T2 DE69900249 T2 DE 69900249T2 DE 69900249 T DE69900249 T DE 69900249T DE 69900249 T DE69900249 T DE 69900249T DE 69900249 T2 DE69900249 T2 DE 69900249T2
Authority
DE
Germany
Prior art keywords
fibrate
metformin
pharmaceutical composition
treating hyperglycaemia
hyperglycaemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69900249T
Other languages
German (de)
English (en)
Other versions
DE69900249D1 (de
Inventor
Yves Bonhomme
Philippe Briet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of DE69900249D1 publication Critical patent/DE69900249D1/de
Application granted granted Critical
Publication of DE69900249T2 publication Critical patent/DE69900249T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69900249T 1998-02-12 1999-01-30 Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie Expired - Lifetime DE69900249T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9801709A FR2774591B1 (fr) 1998-02-12 1998-02-12 Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
PCT/EP1999/000614 WO1999040904A2 (en) 1998-02-12 1999-01-30 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the treatment of hyperglycemia

Publications (2)

Publication Number Publication Date
DE69900249D1 DE69900249D1 (de) 2001-10-04
DE69900249T2 true DE69900249T2 (de) 2002-06-13

Family

ID=9522912

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69900249T Expired - Lifetime DE69900249T2 (de) 1998-02-12 1999-01-30 Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie

Country Status (28)

Country Link
US (1) US6372790B1 (uk)
EP (1) EP1054665B1 (uk)
JP (1) JP4767411B2 (uk)
KR (1) KR100567608B1 (uk)
CN (1) CN1151785C (uk)
AR (1) AR018286A1 (uk)
AT (1) ATE204754T1 (uk)
AU (1) AU746821B2 (uk)
BR (1) BRPI9907866B8 (uk)
CA (1) CA2320039C (uk)
CZ (1) CZ290101B6 (uk)
DE (1) DE69900249T2 (uk)
DK (1) DK1054665T3 (uk)
ES (1) ES2162517T3 (uk)
FR (1) FR2774591B1 (uk)
HK (1) HK1034913A1 (uk)
HU (1) HU224619B1 (uk)
ID (1) ID26254A (uk)
MY (1) MY118164A (uk)
NO (1) NO328314B1 (uk)
PL (1) PL196874B1 (uk)
PT (1) PT1054665E (uk)
RU (1) RU2207850C2 (uk)
SK (1) SK283212B6 (uk)
TW (1) TW518222B (uk)
UA (1) UA70315C2 (uk)
WO (1) WO1999040904A2 (uk)
ZA (1) ZA991077B (uk)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69822505T2 (de) * 1997-12-08 2005-01-20 Bristol-Myers Squibb Co. Neue metformin-salze und verfahren
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
FR2796940B1 (fr) * 1999-07-26 2005-04-08 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP4879433B2 (ja) * 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
JP4829411B2 (ja) * 2001-02-23 2011-12-07 キッセイ薬品工業株式会社 C型慢性肝炎治療剤
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
EP1424070A1 (en) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides
JP2006511525A (ja) 2002-12-13 2006-04-06 ヤゴテック アーゲー ナノ粒子状スピロノラクトン局所製剤
FR2851734B1 (fr) * 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
US8062664B2 (en) * 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
MXPA06007100A (es) 2003-12-19 2007-01-19 Omega Bio Pharma Ip3 Ltd Composiciones y metodos para tratar la diabetes.
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
EP1714648A4 (en) * 2004-02-09 2010-05-26 Aska Pharm Co Ltd COMBINATION DRUGS
EP1591114A1 (en) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
US20060286182A1 (en) * 2005-06-21 2006-12-21 Abeille Pharmaceuticals, Inc. Synergistic cinnamon combinations and methods for enhancing insulin activity
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
BRPI0621942A2 (pt) 2006-08-04 2011-10-18 Aska Pharm Co Ltd preparação que reduz uma concentração de um ácido graxo livre e/ou fibrinogênio no sangue, agente para redução da quantidade de um ácido graxo livre no sangue, agente para redução da quantidade de fibrinogênio no sangue, método de prevenção ou tratamento de hiper-acidemia de ácido graxo livre, sìndrome metabólica, diabetes tipo ii, complicações causadas por diabetes tipo ii, lipotoxicidade, metabolismo anormal de lipìdeos, intoleráncia à glicose, secreção prejudicada de insulina, gordura hepática, lipoproteinemia de hipo-alta densidade, ou trombose, e uso de uma preparação
CN101342164B (zh) * 2007-08-21 2011-04-20 阜新市仙鹤制药有限责任公司 苯扎贝特控释制剂及其制备方法
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
ES2344183B1 (es) * 2009-02-18 2011-06-10 Italfarmaco, S.A. Uso de agentes sensibilizantes a insulina por via vaginal.
US9339458B2 (en) * 2009-02-18 2016-05-17 Itf Research Pharma, S.L.U. Use of vaginal insulin sensitizing agents
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP2012171911A (ja) 2011-02-22 2012-09-10 Kao Corp Ppar活性化剤
EP2872483A4 (en) * 2012-07-10 2016-03-16 Thetis Pharmaceuticals Llc THREE METFORMIN SALT FORM
US8765811B2 (en) * 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) * 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
MX2016016830A (es) 2014-06-18 2017-07-07 Thetis Pharmaceuticals Llc Complejos de aminoacidos minerales de agentes activos.
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
JP6906047B2 (ja) 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
WO2018058109A1 (en) * 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
FR3056908B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
EP3544614A4 (en) 2016-11-28 2020-08-05 Lipocine Inc. ORAL TESTOSTERONE UNDECANOATE THERAPY
GB2599950A (en) * 2020-10-16 2022-04-20 Zentiva Ks Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
WO2023119100A1 (en) * 2021-12-22 2023-06-29 Mankind Pharma Ltd. Stable pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2264525B1 (uk) * 1974-03-22 1977-11-04 Expl Marques Brevets Et
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
DE3729209A1 (de) * 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators

Also Published As

Publication number Publication date
DE69900249D1 (de) 2001-10-04
NO328314B1 (no) 2010-01-25
EP1054665A2 (en) 2000-11-29
PL196874B1 (pl) 2008-02-29
CZ20002828A3 (cs) 2000-11-15
KR20010040925A (ko) 2001-05-15
MY118164A (en) 2004-09-30
ID26254A (id) 2000-12-07
JP2002502869A (ja) 2002-01-29
UA70315C2 (en) 2004-10-15
PT1054665E (pt) 2002-02-28
WO1999040904A3 (en) 1999-09-30
DK1054665T3 (da) 2001-12-27
CA2320039C (en) 2008-07-22
CN1151785C (zh) 2004-06-02
KR100567608B1 (ko) 2006-04-04
HU224619B1 (hu) 2005-11-28
NO20004056L (no) 2000-08-11
AU2923399A (en) 1999-08-30
WO1999040904A2 (en) 1999-08-19
RU2207850C2 (ru) 2003-07-10
BR9907866A (pt) 2000-10-31
FR2774591B1 (fr) 2000-05-05
HUP0100801A3 (en) 2001-12-28
CZ290101B6 (cs) 2002-05-15
FR2774591A1 (fr) 1999-08-13
CN1290160A (zh) 2001-04-04
ZA991077B (en) 1999-08-11
SK283212B6 (sk) 2003-03-04
EP1054665B1 (en) 2001-08-29
AR018286A1 (es) 2001-11-14
PL342665A1 (en) 2001-07-02
BRPI9907866B1 (pt) 2017-08-15
HUP0100801A2 (hu) 2001-08-28
ES2162517T3 (es) 2001-12-16
JP4767411B2 (ja) 2011-09-07
CA2320039A1 (en) 1999-08-19
ATE204754T1 (de) 2001-09-15
NO20004056D0 (no) 2000-08-11
HK1034913A1 (en) 2001-11-09
SK11562000A3 (sk) 2000-12-11
US6372790B1 (en) 2002-04-16
TW518222B (en) 2003-01-21
BRPI9907866B8 (pt) 2021-05-25
AU746821B2 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
DE69900249D1 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE69720463D1 (de) Sulfonamid-derivate und ihre verwendung zur behandlung von zns-erkrankungen
DE69710095D1 (de) Pharmazeutische zubereitung zur behandlung von diabetes
DE69906671D1 (de) Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen
DE60204548D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
ATE318138T1 (de) Pharmazeutisches mittel zur behandlung von diabetes
DE60010456D1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
ATE238342T1 (de) Neue thrombin-inhibitoren, deren herstellung und verwendung
ATE276245T1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
ATE260033T1 (de) Biozide zusammensetzung und deren verwendung
DE69804659T2 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
DE69812784D1 (de) Zusammensetzung zur Vorbeugung und Beseitigung von Pflanzenkrankheiten
DE69841984D1 (de) Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
DE69734296D1 (de) Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b
ATE227278T1 (de) Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
ATE254128T1 (de) Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
ATE234617T1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
ATE264309T1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
DE69925578D1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
DE59806627D1 (de) Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition